{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:17:52Z","timestamp":1768313872089,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.thromres.2021.01.019","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T09:36:21Z","timestamp":1611740181000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Risk of new-onset osteoporosis in single-center veteran population receiving direct oral anticoagulants versus warfarin"],"prefix":"10.1016","volume":"200","author":[{"given":"Tanvi","family":"Patil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2021.01.019_bb0005","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2021.01.019_bb0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1359\/jbmr.070315","article-title":"Residual lifetime risk of fractures in women and men","volume":"22","author":"Nguyen","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.thromres.2021.01.019_bb0015","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1055\/s-0034-1543999","article-title":"Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old?","volume":"41","author":"Tufano","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2021.01.019_bb0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1203\/01.PDR.0000155943.07244.04","article-title":"Reduced bone density in children on long-term warfarin","volume":"57","author":"Barnes","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.thromres.2021.01.019_bb0025","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-128-10-199805150-00006","article-title":"Warfarin use and risk for osteoporosis in elderly women: study of osteoporotic fractures research group","volume":"128","author":"Jamal","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.thromres.2021.01.019_bb0030","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1515\/cclm-2012-0605","article-title":"The role of homocysteine in bone remodeling","volume":"51","author":"Vacek","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"issue":"21","key":"10.1016\/j.thromres.2021.01.019_bb0035","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.3390\/ijms20215275","article-title":"Anticoagulants and osteoporosis","volume":"20","author":"Signorelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.thromres.2021.01.019_bb0040","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00228-017-2296-1","article-title":"Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015","volume":"73","author":"Kjerpeseth","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2021.01.019_bb0045","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2021.01.019_bb0050","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/VHRM.S121661","article-title":"Evaluation of bleeding in patients receiving direct oral anticoagulants","volume":"13","author":"Hellenbart","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"issue":"9921","key":"10.1016\/j.thromres.2021.01.019_bb0055","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.thromres.2021.01.019_bb0060","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.08.1025","article-title":"Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants","volume":"74","author":"Binding","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.thromres.2021.01.019_bb0065","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/eurheartj\/ehz952","article-title":"Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study","volume":"41","author":"Huang","year":"2020","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2021.01.019_bb0070","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamainternmed.2019.5679","article-title":"Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation [published online ahead of print, 2019 Nov 25]","volume":"180","author":"Lutsey","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.thromres.2021.01.019_bb0075","article-title":"Risk of fracture in patients with nonvalvular atrial fibrillation initiating direct oral anticoagulants vs vitamin K antagonists","author":"He","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.thromres.2021.01.019_bb0080","doi-asserted-by":"crossref","unstructured":"Huang HK, Liu PP, Hsu JY, et al. Risk of osteoporosis in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants or warfarin [published correction appears in J. Am. Heart Assoc. 2020 Feb 18;9(4):e014510]. J. Am. Heart Assoc. 2020;9(2):e013845. doi:https:\/\/doi.org\/10.1161\/JAHA.119.013845.","DOI":"10.1161\/JAHA.119.014510"},{"key":"10.1016\/j.thromres.2021.01.019_bb0085","doi-asserted-by":"crossref","unstructured":"Yokoyama S, Ieda S, Nagano M, et al. Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. Int J. Med. Sci. 2020;17(4):471\u2013479. Published 2020 Feb 4. doi:https:\/\/doi.org\/10.7150\/ijms.39523.","DOI":"10.7150\/ijms.39523"},{"issue":"2","key":"10.1016\/j.thromres.2021.01.019_bb0090","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2021.01.019_bb0095","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.thromres.2021.01.019_bb0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.thromres.2021.01.019_bb0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/MLR.0000000000000729","article-title":"Development of a claims-based frailty Indicator anchored to a well-established frailty phenotype [published correction appears in Med. Care. 2017 Dec;55(12):1062]","volume":"55","author":"Segal","year":"2017","journal-title":"Med. Care"},{"issue":"8","key":"10.1016\/j.thromres.2021.01.019_bb0110","first-page":"1257","article-title":"The burden of frailty among U.S. veterans and its association with mortality","volume":"74","author":"Orkaby","year":"2002","journal-title":"The Journals of Gerontology: Series A"},{"issue":"9","key":"10.1016\/j.thromres.2021.01.019_bb0115","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/pds.3674","article-title":"Measuring frailty using claims data for pharmacoepidemiologic studies of mortality in older adults: evidence and recommendations","volume":"23","author":"Kim","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.thromres.2021.01.019_bb0120","first-page":"188","article-title":"Charlson comorbidity index: ICD-9 update and ICD-10 translation","volume":"12","author":"Glasheen","year":"2019","journal-title":"Am. Health Drug Benefits"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2021.01.019_bb0125","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/pds.3263","article-title":"One-to-many propensity score matching in cohort studies","volume":"21","author":"Rassen","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.thromres.2021.01.019_bb0130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm. Stat."},{"issue":"1","key":"10.1016\/j.thromres.2021.01.019_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika."},{"key":"10.1016\/j.thromres.2021.01.019_bb0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl. J. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:44:39Z","timestamp":1758735879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":28,"alternative-id":["S0049384821000384"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.01.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of new-onset osteoporosis in single-center veteran population receiving direct oral anticoagulants versus warfarin","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}